Saturday 17 October 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024. In the quarter to March 2026, revenue fell 66.3%, EPS grew 103.6%, free cash flow grew 148.4% and total debt fell 4.73%, each against the same quarter a year earlier.
1.25
0.08
−6.02%
Follow CELU
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.04 | 1.07 | 1.34 | 1.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
26.72 | (5.57) | (13.11) | (47.13) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.19 | 2.64 | 2.33 | 2.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.01) | (5.29) | (14.39) | (35.27) | |
EV/FCF |
(8.85) | (5.22) | (14.05) | (33.17) | |
Quick Ratio |
0.07 | 0.13 | 0.10 | 0.17 | |
Current Ratio |
0.09 | 0.15 | 0.16 | 0.25 | |
Net Debt/EBITDA |
(4.77) | (2.06) | (3.58) | (3.03) | |
Debt/Assets |
41.32% | 44.55% | 34.98% | 36.11% | |
Debt/Equity |
(1.17) | (1.26) | (1.99) | (1.70) | |
Asset Turnover |
0.17 | 0.22 | 0.33 | 0.35 | |
Operating CF/Net income |
2.14 | 0.21 | 0.18 | 0.04 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(28.79) | (24.59) | (8.73) | (8.16) | |
Research and Development Expense of Revenue |
77.85% | 81.55% | 87.02% | 58.44% | |
Selling, General and Administrative Expense of Revenue |
238.30% | 367.06% | 176.12% | 220.26% | |
Intangible Assets out of Total Assets |
0.15 | 0.14 | 0.14 | 0.13 | |
Share Based Compensation of Revenue |
32.32% | 79.24% | 38.63% | 42.68% | |
Graham Net Nets |
(3.32) | (4.68) | (2.27) | (2.73) | |
Graham Number |
8.61 | 10.95 | 7.56 | 8.71 | |
Earnings Yield |
(204.24%) | (323.11%) | (160.87%) | (162.24%) | |
Free Cash Flow Yield |
(23.21%) | (47.21%) | (12.32%) | (5.74%) | |
Revenue per Share |
0.13 | 0.16 | 0.20 | 0.24 | |
Operating CF per Share |
0.05 | (0.20) | (0.16) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.05 | (0.20) | (0.16) | (0.04) | |
Cash per Share |
0.01 | 0.24 | 0.00 | 0.04 | |
Shareholders Equity per Share |
(1.21) | (1.49) | (0.76) | (1.06) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.21) | (1.49) | (0.76) | (1.06) | |
Free Cash Flow |
1.45 | (5.10) | (4.16) | (1.00) | |
Working Capital |
(64.28) | (68.44) | (54.72) | (51.96) | |
Net Current Asset Value |
(128.44) | (133.07) | (123.74) | (128.52) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.87 | 9.11 | 7.74 | 12.31 | |
Average Payables |
24.21 | 24.86 | 19.99 | 19.06 | |
Average Inventory |
3.34 | 2.99 | 3.26 | 3.66 | |
Average Assets |
114.18 | 120.01 | 121.54 | 127.89 | |
Average Common Equity |
(20.38) | (14.61) | (1.41) | 1.16 |
Columns are period end dates · fundamentals updated 1 Oct 2026